OXIDATIVE STRESS AND CANCER
##plugins.themes.vojs.article.main##
Abstract
Oxidative stress can be defi ned as an imbalance between free radicals or reactive oxygen species and antioxidants. The balance of reactive oxygen species generation and elimination is maintained by antioxidants. Antioxidants are molecules that signifi cantly delay or inhibit oxidation. The main causes
of oxidative stress are exogenous source such as diet, alcohol, stress, environmental pollution, smoke, radiation, medication and treatment, excessive of physical activity. Chronic oxidative stress aff ects to biological molecules, as oxidation of lipid, carbohydrate, enzymes, and damage of protein and DNA,
altered redox regulation, leading to infl ammation, a range of diseases and aging. Oxidative stress is closely related to all aspects of cancer, such as carcinogenesis, tumor-bearing state, treatment and prevention. Oxidative stress aff ects to carcinogenesis through two mechanisms, gene mutation that results from oxidized DNA, and gene extression change due to injured DNA binding to transcription factors. Some oxidative stress markers are considered as tumor markers, that are applied to diagnosis tumor-bearing state. Main mechanisms of anticancer drugs is creating apoptosis. Treatment with anticancer drugs creates oxidative stress, and active oxygen triggers apoptosis via p53 and cytochrome release from mitochondria. It is possible that excessive antioxidation mechnisms take part in anticancer drug resistance. Increasing antioxidants for protection against oxidative stress damage, inhibition of
nonspecifi c infl ammaton, and prevention of oxidative stresss are also useful in prevention of cancer.
##plugins.themes.vojs.article.details##
Keywords
Oxidative, stress, free radical, reactive oxygen specie, antioxidant.
References
2. Drog W, 2002. Free radicals in physiological control of cell function. Physiol Rev; 82: 47 - 95.
3. Cadenas E, Davies KJ. 2000. Mitochondrial free radical generation, oxidative stress and
aging. Free Radical Biol Med.; 62 : 220 - 230.
4. Valko M J, Leibfritz D, Moncol. J. et al. 2007. Free radicals and antioxidants in normal
physiological functions and human disease. Int. J. Biochem Cell Biol; 39(1): 44 - 84.
5. Galls F, Piroddi M, Annatti C, Aisa C, Floridi E. and Floridi A 2005. Oxidative stress and reactive
oxygen species. Contrib Nephrol; 149: 240 - 260.
6. Adwwas Â, Elsayed ASI, Azab AE, et al. 2019. Oxidative stress and antioxidant mechanisms in
human body. J. Appl. Biotechnol Bioeng; 6(1):43 - 47.
7. Amira AM Adly. 2005. Oxidative Stress and Disease: An update Review. Research Journal of
Immunology; 3: 129-145.
8. Ahmet A. 2015. Oxidative stress and Overview of Pediatric Biomarkers. J; of Pediatr;
5: 8.
9. Avery AV, 2011. Molecular targets of oxidative stress. Biochem J; 434(2) : 201-210.
10. Finkel F, Holbrook NJ. 2000. Oxidants, oxidative stress and the biology of ageing.
Nature; 408: 239-247.
11. Noda N, Wakasugi H, 2000. Canser and oxidative stress. Journal of Japan Medical
Asociation; 124(11): 1571-1574.
12. Ambrosone CB, Freudenheim JL, Thompson PA, et al. 1999. Mangane superoxide
dismutase (MnSOD) genetic polymorphisms, dietary antioxidants, and risk of breast cancer.
Cancer Resp; 59: 602-606.
13. Chen X, Ding JW, Yang Gy, et al. 2000. Oxidative damagein an esophageal
adenocarcinoma models with rats. Carcinogenesis; 21: 257-263.
14. Pignatelli B, Bancel B, Esteve J, et al. 1998. Inducible nitric oxide synthase, anti-oxidant
enzymes and Helicobacter poylori infection in gastritis and gastric precancerous lesions in
humans. Euro J Cancer Prev; 7: 439-447.
15. Ishikawa M, Tamate K and Sengoku K. 1999. Free radicals and disease. Disease in
obstetrics and gynecology. Gendai Iryo; 31: 2579-2585 (in Japanese).
16. Miyazaki E Noda N, Okada S, et al. 1998. Elevated serum level of thioredoxin in patients
with hepatocellular carcinoma. Biotherapy; 11 :277-288.
17. Yokomizo A, Ono M, Nanri H, et al. 1995. Cellular levels of thioredoxin associated with drug
sensitive to cisplatin, mitomycin C, doxorubicin, and etoposide. Cancer Res; 55: 4293-4296.
18. Weijl NI, Hopman GD, Wipkink-Blakker A, et al. 1998. Cisplatin combination chemotherapy
induces a fall in plasma antioxidants of cancer patients. Ann Oncol; 9: 1331-1337.
19. Terry P, Lagergren J, Ye W. et al. 2000. Antioxidants and cancers of the esophagus and
gastric cardia. Int J Cancer; 87: 750-754,
20. Kimura I, Kumamoto T, Matsuda A, et al. 1998. Eff ects of BX 661 A, a new therapeutic agent
for ulcerative colitis, on reactive oxygenin species in comparison with salazosulfapyridine and its
metabolite sulfapyridine. Arzneimittelforshung; 48: 1007-1011.